[{"id":"fa762180-1ac0-4c2f-bfff-1035ccc3f515","acronym":"","url":"https://clinicaltrials.gov/study/NCT05669664","created_at":"2023-12-04T19:35:23.503Z","updated_at":"2025-02-25T15:20:12.831Z","phase":"Phase 2","brief_title":"Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers","source_id_and_acronym":"NCT05669664","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 04/11/2027","primary_completion_date":" 04/11/2027","study_txt":" Completion: 04/11/2027","study_completion_date":" 04/11/2027","last_update_posted":"2025-02-12"},{"id":"a8e4ef32-1344-482b-a5f5-187c3f5e9c87","acronym":"YATAGARASU","url":"https://clinicaltrials.gov/study/NCT04325828","created_at":"2021-01-18T20:57:18.226Z","updated_at":"2025-02-25T15:26:19.647Z","phase":"Phase 2","brief_title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT04325828 - YATAGARASU","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 06/09/2021","primary_completion_date":" 06/09/2021","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"ffa36ee9-c0da-420e-bc20-b503b2b0b217","acronym":"TBCRC 058","url":"https://clinicaltrials.gov/study/NCT06099769","created_at":"2023-10-25T19:14:04.278Z","updated_at":"2025-02-25T15:36:36.074Z","phase":"Phase 2","brief_title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","source_id_and_acronym":"NCT06099769 - TBCRC 058","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PD-L1 • AR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • AR positive","tags":["HER-2 • PD-L1 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • capecitabine • Xtandi (enzalutamide) • Halaven (eribulin mesylate) • Korlym (mifepristone) • Mifeprex (mifepristone)"],"overall_status":"Recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-01-20"},{"id":"ff675977-05eb-4cd0-95e9-0479db1dd928","acronym":"CA209-8H3","url":"https://clinicaltrials.gov/study/NCT03650894","created_at":"2021-01-18T17:55:05.836Z","updated_at":"2025-02-25T14:27:31.343Z","phase":"Phase 2","brief_title":"Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients","source_id_and_acronym":"NCT03650894 - CA209-8H3","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 negative • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • bicalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-10-26"},{"id":"204a3645-717f-42ed-9810-3a60efcecc4a","acronym":"BTCRC-HN17-111","url":"https://clinicaltrials.gov/study/NCT03942653","created_at":"2021-01-18T19:24:28.517Z","updated_at":"2025-02-25T16:09:07.413Z","phase":"Phase 2","brief_title":"Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT03942653 - BTCRC-HN17-111","lead_sponsor":"Manish Patel","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-10-11"},{"id":"41b730ba-cb49-45dd-837c-967e8c4c2b8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03090165","created_at":"2021-01-18T15:13:36.654Z","updated_at":"2025-02-25T15:53:41.650Z","phase":"Phase 1/2","brief_title":"Ribociclib and Bicalutamide in AR+ TNBC","source_id_and_acronym":"NCT03090165","lead_sponsor":"Kari Wisinski","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" HER-2 negative • AR positive • HER-2 negative + ER positive","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-10-11"},{"id":"db437829-c154-4ef1-a95d-32ea4e2d953d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02676986","created_at":"2021-01-18T13:03:06.360Z","updated_at":"2025-02-25T15:33:36.075Z","phase":"Phase 2","brief_title":"Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer","source_id_and_acronym":"NCT02676986","lead_sponsor":"Queen Mary University of London","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" AR positive • AR expression","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive • AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 08/10/2015","start_date":" 08/10/2015","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2024-07-04"},{"id":"893db886-c712-4cce-b597-bb3b00601a44","acronym":"DISCOVARY","url":"https://clinicaltrials.gov/study/NCT05694819","created_at":"2023-01-23T14:59:43.274Z","updated_at":"2025-02-25T17:25:58.308Z","phase":"Phase 2","brief_title":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","source_id_and_acronym":"NCT05694819 - DISCOVARY","lead_sponsor":"National Cancer Center Hospital East","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/17/2020","start_date":" 04/17/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-06-21"},{"id":"acac02cd-c592-4eb3-b05a-a4f2485bc521","acronym":"DUCT","url":"https://clinicaltrials.gov/study/NCT05513365","created_at":"2022-08-24T21:07:35.191Z","updated_at":"2024-07-02T16:35:07.770Z","phase":"Phase 2","brief_title":"Phase II Dutasteride in Combination With CAB vs CAB in SDC","source_id_and_acronym":"NCT05513365 - DUCT","lead_sponsor":"Radboud University Medical Center","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bicalutamide • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-04-24"},{"id":"3389546b-7889-41d7-a623-1ac7e9ef8f61","acronym":"","url":"https://clinicaltrials.gov/study/NCT05924256","created_at":"2023-06-29T14:09:00.727Z","updated_at":"2024-07-02T16:35:14.639Z","phase":"Phase 2","brief_title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","source_id_and_acronym":"NCT05924256","lead_sponsor":"Fudan University","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-03-15"},{"id":"ae5a0e32-c5dd-4ae6-83e1-84b2f1b61b9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02971761","created_at":"2021-01-18T14:36:31.515Z","updated_at":"2024-07-02T16:35:18.941Z","phase":"Phase 2","brief_title":"Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT02971761","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" HER-2 negative • AR positive • ER expression • PGR expression","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ostarine (enobosarm)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 10/28/2020","primary_completion_date":" 10/28/2020","study_txt":" Completion: 08/16/2022","study_completion_date":" 08/16/2022","last_update_posted":"2024-02-19"},{"id":"512fe4d7-03cf-43f6-a891-9c37a20aec55","acronym":"","url":"https://clinicaltrials.gov/study/NCT03207529","created_at":"2021-01-18T15:48:40.498Z","updated_at":"2024-07-02T16:35:23.801Z","phase":"Phase 1","brief_title":"Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT03207529","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR • PTEN • AR","pipe":" | ","alterations":" HR positive • HER-2 negative • AR positive • PTEN positive","tags":["HER-2 • ER • PGR • PTEN • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • AR positive • PTEN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-01-11"},{"id":"1ec6fe87-88eb-4f6f-aa47-66e2b9835ddb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02689427","created_at":"2021-01-18T13:07:04.373Z","updated_at":"2024-07-02T16:35:28.856Z","phase":"Phase 2","brief_title":"Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02689427","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 amplification • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/22/2016","start_date":" 09/22/2016","primary_txt":" Primary completion: 11/15/2023","primary_completion_date":" 11/15/2023","study_txt":" Completion: 11/15/2023","study_completion_date":" 11/15/2023","last_update_posted":"2023-11-17"},{"id":"e61a842e-3393-4ae3-9685-c52db2616f42","acronym":"4CAST","url":"https://clinicaltrials.gov/study/NCT04947189","created_at":"2021-07-01T14:54:41.667Z","updated_at":"2024-07-02T16:35:33.448Z","phase":"Phase 1b","brief_title":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT04947189 - 4CAST","lead_sponsor":"St Vincent's Hospital, Sydney","biomarkers":" HER-2 • PGR • AR","pipe":" | ","alterations":" HR positive • HER-2 negative • AR positive • EGFR positive","tags":["HER-2 • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • AR positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • dexamethasone • seviteronel (INO-464)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-16"},{"id":"86910daf-559d-4d54-870d-bff8653e3b13","acronym":"TASUC-Neo","url":"https://clinicaltrials.gov/study/NCT05839119","created_at":"2023-05-03T15:04:23.772Z","updated_at":"2024-07-02T16:35:34.468Z","phase":"Phase 1","brief_title":"Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant","source_id_and_acronym":"NCT05839119 - TASUC-Neo","lead_sponsor":"Brown University","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Firmagon (degarelix)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-10-06"},{"id":"7a4df5f8-d679-43c6-a55a-2239edf5514e","acronym":"UCBG3-06 START","url":"https://clinicaltrials.gov/study/NCT03383679","created_at":"2021-01-18T16:41:49.948Z","updated_at":"2024-07-02T16:36:00.149Z","phase":"Phase 2","brief_title":"Study on Androgen Receptor and Triple Negative Breast Cancer","source_id_and_acronym":"NCT03383679 - UCBG3-06 START","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" HER-2 negative • AR positive","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Nubeqa (darolutamide)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 03/14/2018","start_date":" 03/14/2018","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2022-11-21"},{"id":"b70042f0-4b62-4d67-8497-8d36d3815116","acronym":"ADT-SCAN","url":"https://clinicaltrials.gov/study/NCT04214353","created_at":"2021-01-18T20:31:17.214Z","updated_at":"2024-07-02T16:36:05.395Z","phase":"","brief_title":"PSMA-PET Imaging Before and After ADT in Advanced SDC Patients","source_id_and_acronym":"NCT04214353 - ADT-SCAN","lead_sponsor":"Radboud University Medical Center","biomarkers":" AR • FOLH1","pipe":" | ","alterations":" AR positive • FOLH1 expression","tags":["AR • FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive • FOLH1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 01/14/2020","start_date":" 01/14/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2022-08-16"},{"id":"bac307eb-8b56-473a-95bd-7b6ec2732fb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00468715","created_at":"2021-01-18T01:39:59.341Z","updated_at":"2025-02-25T15:03:41.417Z","phase":"Phase 2","brief_title":"Bicalutamide in Treating Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT00468715","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" AR positive","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bicalutamide"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 03/23/2007","start_date":" 03/23/2007","primary_txt":" Primary completion: 06/24/2021","primary_completion_date":" 06/24/2021","study_txt":" Completion: 06/24/2021","study_completion_date":" 06/24/2021","last_update_posted":"2022-08-03"},{"id":"12afa15f-7965-45d2-ae3a-ebcbd432c421","acronym":"","url":"https://clinicaltrials.gov/study/NCT04103853","created_at":"2021-01-18T20:04:18.339Z","updated_at":"2024-07-02T16:36:24.021Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer","source_id_and_acronym":"NCT04103853","lead_sponsor":"Suzhou Kintor Pharmaceutical Inc,","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pruxelutamide (GT0918)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2021-09-24"},{"id":"935757e6-fc4c-43e2-b81d-6a4188538dfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01842321","created_at":"2021-01-18T08:12:38.375Z","updated_at":"2024-07-02T16:36:34.231Z","phase":"Phase 2","brief_title":"Abiraterone Acetate in Molecular Apocrine Breast Cancer","source_id_and_acronym":"NCT01842321","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" HER-2 negative • AR positive","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 07/15/2015","primary_completion_date":" 07/15/2015","study_txt":" Completion: 07/04/2018","study_completion_date":" 07/04/2018","last_update_posted":"2021-02-23"},{"id":"10c522a4-7c06-4153-868b-868983a40f3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02463032","created_at":"2021-01-18T11:49:15.311Z","updated_at":"2024-07-02T16:36:37.559Z","phase":"Phase 2","brief_title":"Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer","source_id_and_acronym":"NCT02463032","lead_sponsor":"GTx","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" ER positive • HER-2 negative • AR positive","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ostarine (enobosarm)"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-12-09"},{"id":"a95b6e57-9a71-4897-a32d-ead308f80cf7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02697032","created_at":"2021-01-18T13:09:57.569Z","updated_at":"2024-07-02T16:36:53.136Z","phase":"Phase 2","brief_title":"FDHT PET and Bicalutamide in Metastatic Breast Cancer","source_id_and_acronym":"NCT02697032","lead_sponsor":"University Medical Center Groningen","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 negative • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bicalutamide"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 11/25/2019","primary_completion_date":" 11/25/2019","study_txt":" Completion: 11/25/2019","study_completion_date":" 11/25/2019","last_update_posted":"2019-11-27"},{"id":"25170b14-2ea2-49b0-acfc-f00d60de235f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02130700","created_at":"2021-01-18T09:53:00.309Z","updated_at":"2024-07-02T16:37:10.952Z","phase":"Phase 2","brief_title":"Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer","source_id_and_acronym":"NCT02130700","lead_sponsor":"Innocrin Pharmaceutical","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • seviteronel (INO-464)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2018-05-07"},{"id":"f2b73116-096b-4f6e-aa4f-927210f18151","acronym":"NeoGONT","url":"https://clinicaltrials.gov/study/NCT03444025","created_at":"2021-01-18T16:59:00.797Z","updated_at":"2024-07-02T16:37:13.698Z","phase":"Phase 2","brief_title":"Neoadjuvant Goserelin for Triple Negative Breast Cancer","source_id_and_acronym":"NCT03444025 - NeoGONT","lead_sponsor":"Kasr El Aini Hospital","biomarkers":" HER-2 • PGR • AR","pipe":" | ","alterations":" HER-2 negative • AR positive • PGR negative","tags":["HER-2 • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • goserelin acetate"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2018-02-23"}]